| Dr Zhao Liu, MD | |
|
404 N Keene St Ste 101, Columbia, MO 65201-6626 | |
| (573) 882-6921 | |
| (573) 884-9833 |
| Full Name | Dr Zhao Liu |
|---|---|
| Gender | Male |
| Speciality | Psychiatry & Neurology - Neurology With Special Qualifications In Child Neurology |
| Location | 404 N Keene St Ste 101, Columbia, Missouri |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1114963394 | NPI | - | NPPES |
| 200091430 | Medicaid | MO | |
| 273192400 | Medicaid | FL |
| Entity Name | The Board Of Trustees Of The University Of Illinois |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1386863819 PECOS PAC ID: 3072422716 Enrollment ID: O20031112000158 |
News Archive
People newly diagnosed with cancer, particularly blood cancers, and those treated with chemotherapy have a greater risk of developing shingles, according to a new study in the Journal of Infectious Diseases.
International Stem Cell Corporation, announced today that it had entered into a Memorandum of Understanding with ARG Vermogensverwaltung AG, a German Investment Fund, to create a new European subsidiary ("ISCO Europe") to be funded with up to $10 million of capital derived from ARG and other independent sources in Europe. Shares of ISCO Europe are expected to trade on the Deutsche Bourse independently of the company's shares in the US. ISCO Europe's shares will not be convertible into ISCO shares on any US exchange.
Newron Pharmaceuticals S.p.A. ("Newron"), a research and development company focused on novel CNS and pain therapies, and its partner Zambon S.p.A., a pharmaceutical company strongly committed to the respiratory, primary care and CNS therapeutic areas, presented results from SETTLE Phase III study with safinamide at the 17th International Congress of Parkinson's disease and Movement Disorders, taking place from June 16 to 20, 2013, at the Sydney Convention and Exhibition Centre, Sydney, Australia.
Lux Biosciences, Inc., a privately held biotechnology company focused on the development and commercialization of therapies for serious ophthalmic diseases, today announced that the company's experimental drug LX211 (LUVENIQ; oral voclosporin) will be featured in several presentations at the 2009 American Academy of Ophthalmology annual conference and American Uveitis Society meeting being held October 24-26 in San Francisco.
A team of scientists describe the safety and response to REGEN-COV® for COVID-19 patients with immunodeficiency-associated antibody disorders.
› Verified 5 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Zhao Liu, MD Po Box 843966, Kansas City, MO 64184-3966 Ph: (573) 884-3300 | Dr Zhao Liu, MD 404 N Keene St Ste 101, Columbia, MO 65201-6626 Ph: (573) 882-6921 |
News Archive
People newly diagnosed with cancer, particularly blood cancers, and those treated with chemotherapy have a greater risk of developing shingles, according to a new study in the Journal of Infectious Diseases.
International Stem Cell Corporation, announced today that it had entered into a Memorandum of Understanding with ARG Vermogensverwaltung AG, a German Investment Fund, to create a new European subsidiary ("ISCO Europe") to be funded with up to $10 million of capital derived from ARG and other independent sources in Europe. Shares of ISCO Europe are expected to trade on the Deutsche Bourse independently of the company's shares in the US. ISCO Europe's shares will not be convertible into ISCO shares on any US exchange.
Newron Pharmaceuticals S.p.A. ("Newron"), a research and development company focused on novel CNS and pain therapies, and its partner Zambon S.p.A., a pharmaceutical company strongly committed to the respiratory, primary care and CNS therapeutic areas, presented results from SETTLE Phase III study with safinamide at the 17th International Congress of Parkinson's disease and Movement Disorders, taking place from June 16 to 20, 2013, at the Sydney Convention and Exhibition Centre, Sydney, Australia.
Lux Biosciences, Inc., a privately held biotechnology company focused on the development and commercialization of therapies for serious ophthalmic diseases, today announced that the company's experimental drug LX211 (LUVENIQ; oral voclosporin) will be featured in several presentations at the 2009 American Academy of Ophthalmology annual conference and American Uveitis Society meeting being held October 24-26 in San Francisco.
A team of scientists describe the safety and response to REGEN-COV® for COVID-19 patients with immunodeficiency-associated antibody disorders.
› Verified 5 days ago
Dr. Anasseril E Daniel, MD Psychiatry & Neurology Medicare: Not Enrolled in Medicare Practice Location: 33 E Broadway Ste 115, Columbia, MO 65203 Phone: 573-443-6930 Fax: 573-875-4272 | |
Dr. Joseph J. Parks, M.D. Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: Family Health Center Of Boone County, 1001 West Worley, Columbia, MO 35203 Phone: 573-214-2314 Fax: 573-814-2784 | |
Dr. Robert Edward Frazier, M.D. Psychiatry & Neurology Medicare: Not Enrolled in Medicare Practice Location: 367 Crown Pt, Columbia, MO 65203 Phone: 573-442-4346 Fax: 573-443-2027 | |
Myles Brandon Goble, MD Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 525 N. Keene Street, Suite 301, Columbia, MO 65201 Phone: 573-882-2260 Fax: 573-884-4249 | |
Ashutosh Pandey, MD Psychiatry & Neurology Medicare: Not Enrolled in Medicare Practice Location: 1020 Hitt St, Columbia, MO 65212 Phone: 573-882-1515 | |
Jeffrey Thiele, MD Psychiatry & Neurology Medicare: Not Enrolled in Medicare Practice Location: 800 Hospital Dr, Columbia, MO 65201 Phone: 573-814-6000 | |
Lisa A Lacey, D.O. Psychiatry & Neurology Medicare: Not Enrolled in Medicare Practice Location: 800 Hospital Dr, Columbia, MO 65201 Phone: 573-814-6480 |